Your browser doesn't support javascript.
The Impact of Early Phase COVID-19 Vaccination on Hospitalized COVID-19 Patients.
Taha Güllü, Yusuf; Kulucan, Ebru; Tibel Tuna, Nazmiye; Köksal, Nurhan; Koca, Nizameddin.
  • Taha Güllü Y; Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University.
  • Kulucan E; Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University.
  • Tibel Tuna N; Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University.
  • Köksal N; Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University.
  • Koca N; Department of Internal Medicine, Bursa Yüksek Ihtisas Training and Research Hospital, University of Health Sciences.
Tohoku J Exp Med ; 257(2): 147-151, 2022 Jun 08.
Article in English | MEDLINE | ID: covidwho-2259805
ABSTRACT
The number of cases of coronavirus disease-2019 (COVID-19) globally is over 225 million, and disease-related deaths are over 4 million. The type, prevalence, and antibody susceptibility of the virus variants of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the vaccination rate and coverage are considered critical factors in the progress of COVID-19. We aimed to compare the clinical and laboratory parameters of the patients hospitalized due to COVID-19 in pre-vaccination and post-vaccination periods. We conducted this retrospective cross-sectional study in a tertiary clinic in Turkey. The files of the patients over the age of 18, whose real-time polymerase chain reaction (RT-PCR) tests were positive and who were hospitalized before (November-December 2020, Group 1) and after (March-April 2021, Group 2) COVID-19 vaccination were scanned. Patients' demographical data, clinical severity, laboratory parameters, thorax computed tomography involvement, and mortalities were recorded. The obtained data were compared among the groups. 601 patients (344 male, 57% and 257 female, 43%) were included in the study. It was observed that the patients in the Group 2 were younger (60.71 ± 14.06 vs. 66.95 ± 14.57, p < 0.001), and a significant decrease in mortality [83 (28.6%) vs.139 (44.6%), p = 0.001] were observed in Group 2. The number of patients who needed ventilatory support and the rate of pulmonary involvement was lesser in Group 2, but the difference was non-significant. C-reactive protein, D-dimer, procalcitonin levels were significantly lower in Group 2 patients. Our study shows that the age and mortality of hospitalized COVID-19 patients decreased significantly after vaccination. An increase in the number of booster doses in individuals with advanced age (age > 75) and comorbidity (especially malignancy) may contribute to the control of the disease and immunity in this population.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Tohoku J Exp Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Tohoku J Exp Med Year: 2022 Document Type: Article